Differential gene expression profiling reveals potential biomarkers and pharmacological compounds against SARS-CoV-2: insights from machine learning and bioinformatics approaches
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
SARS-CoV-2 continues to spread and evolve worldwide, despite intense efforts to develop multiple vaccines and therapeutic options against COVID-19. Moreover, the precise role of SARS-CoV-2 in the pathophysiology of the nasopharyngeal tract (NT) is still unfathomable. Therefore, we used the machine learning methods to analyze 22 RNA-seq datasets from COVID-19 patients (n=8), recovered individuals (n=7), and healthy individuals (n=7) to find disease-related differentially expressed genes (DEGs). In comparison to healthy controls, we found 1960 and 153 DEG signatures in COVID-19 patients and recovered individuals, respectively. We compared dysregulated DEGs to detect critical pathways and gene ontology (GO) connected to COVID-19 comorbidities. In COVID-19 patients, the DEG– miRNA and DEG–transcription factors (TFs) interactions network analysis revealed that E2F1, MAX, EGR1, YY1, and SRF were the most highly expressed TFs, whereas hsa-miR-19b, hsa-miR-495, hsa-miR-340, hsa-miR-101, and hsa-miR-19a were the overexpressed miRNAs. Three chemical agents (Valproic Acid, Alfatoxin B1, and Cyclosporine) were abundant in COVID-19 patients and recovered individuals. Mental retardation, mental deficit, intellectual disability, muscle hypotonia, micrognathism, and cleft palate were the significant diseases associated with COVID-19 by sharing DEGs. Finally, we detected DEGs impacted by SARS-CoV-2 infection and mediated by TFs and miRNA expression, indicating that SARS-CoV-2 infection may contribute to various comorbidities. These pathogenetic findings can provide some crucial insights into the complex interplay between COVID-19 and the recovery stage and support its importance in the therapeutic development strategy to combat against COVID-19 pandemic.
IMPORTANCE
Despite it has now been over two years since the beginning of the COVID-19 pandemic, many crucial questions about SARS-CoV-2 infection and the different COVID-19 symptoms it causes remain unresolved. An intriguing question about COVID-19 is how SARS-CoV-2 interplays with the host during infection and how SARS-CoV-2 infection can cause so many disease symptoms. Our analysis of three different datasets (COVID-19, recovered, and healthy) revealed significantly higher DEGs in COVID-19 patients than recovered humans and healthy controls. Some of these DEGs were found to be co-expressed in both COVID-19 patients. They recovered humans supporting the notion that DEGs level is directly correlated with the viral load, disease progression, and different comorbidities. The protein-protein interaction consisting of 24 nodes and 72 edges recognized eight hub-nodes as potential hub-proteins (i.e., RPL4, RPS4X, RPL19, RPS12, RPL19, EIF3E, MT-CYB, and MT-ATP6). Protein–chemical interaction analysis identified three chemical agents (e.g., Valproic Acid, Alfatoxin B1, and Cyclosporine) enriched in COVID-19 patients and recovered individuals. Mental retardation, mental deficiency, intellectual disability, muscle hypotonia, micrognathism, and cleft palate were the significant diseases associated with COVID-19 by sharing DEGs.
Article activity feed
-
SciScore for 10.1101/2022.03.30.486356: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
Software and Algorithms Sentences Resources The BioJupies generator online server (https://maayanlab.cloud/biojupies/) was used for RNA-seq raw data analysis [1]. BioJupiessuggested: (BioJupies, RRID:SCR_016346)Functional enrichment analysis: We utilized Enrichr [3] with Fisher’s exact test to conduct the functional enrichment analysis with the combined DEGs. Enrichrsuggested: (Enrichr, RRID:SCR_001575)In Enrichr analysis, we combined the signaling pathways from two libraries, including KEGG and Reactome, to create a single route. KEGGsuggested: (KEGG, RRID:SCR_012773)Protein-protein interaction network analysis: The shared DEGs’ … SciScore for 10.1101/2022.03.30.486356: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
Software and Algorithms Sentences Resources The BioJupies generator online server (https://maayanlab.cloud/biojupies/) was used for RNA-seq raw data analysis [1]. BioJupiessuggested: (BioJupies, RRID:SCR_016346)Functional enrichment analysis: We utilized Enrichr [3] with Fisher’s exact test to conduct the functional enrichment analysis with the combined DEGs. Enrichrsuggested: (Enrichr, RRID:SCR_001575)In Enrichr analysis, we combined the signaling pathways from two libraries, including KEGG and Reactome, to create a single route. KEGGsuggested: (KEGG, RRID:SCR_012773)Protein-protein interaction network analysis: The shared DEGs’ protein-protein interaction (PPI) was analyzed using the STRING database [4]. STRINGsuggested: (STRING, RRID:SCR_005223)We applied different local- and global-based methods using the cytoHubba plugin [5] in Cytoscape v3.8.2 [6] to determine potential hubs proteins within the PPI network. cytoHubbasuggested: (cytoHubba, RRID:SCR_017677)Finally, the protein networks were analyzed through Cytoscape v3.8.2. Cytoscapesuggested: (Cytoscape, RRID:SCR_003032)Using the shared DEGs, we constructed the protein-drug interaction (PDI) network through the NetworkAnalyst v3.0 web server [7] in conjunction with the DrugBank v5.0 database (https://go.drugbank.com/docs/drugbank_v5.0.xsd). NetworkAnalystsuggested: (NetworkAnalyst, RRID:SCR_016909)DrugBanksuggested: (DrugBank, RRID:SCR_002700)Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- No funding statement was detected.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-